AN2 Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 25, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized on March 25, 2025.
| AN2 Therapeutics, Inc. | |
| By: | /s/ Eric Easom |
| Eric Easom | |
| Chief Executive Officer and Director | |
| (Principal Executive Officer) | |
| By: | /s/ Lucy O. Day |
| Lucy O. Day | |
| Chief Financial Officer | |
| (Principal Financial and Accounting Officer) |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Eric Easom and Lucy O. Day, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Eric Easom | Chief Executive Officer, Chair and Director(Principal Executive Officer) | March 25, 2025 |
| Eric Easom | ||
| /s/ Lucy O. Day | Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | March 25, 2025 |
| Lucy O. Day | ||
| /s/ Maggie FitzPatrick | Lead Independent Director | March 25, 2025 |
| Maggie FItzPatrick | ||
| /s/ Kabeer Aziz | Director | March 25, 2025 |
| Kabeer Aziz | ||
| /s/ Gilbert L. Marks | Director | March 25, 2025 |
| Gilbert L. Marks | ||
| /s/ Patricia (Patty) Martin | Director | March 25, 2025 |
| Patricia (Patty) Martin | ||
| /s/ Rob Readnour | Director | March 25, 2025 |
| Rob Readnour | ||
| /s/ Melvin Spigelman | Director | March 25, 2025 |
| Melvin Spigelman | ||
| /s/ Stephanie Wong | Director | March 25, 2025 |
| Stephanie Wong | ||
| /s/ Joseph Zakrzewski | Director | March 25, 2025 |
|---|---|---|
| Joseph Zakrzewski | ||
INDEX TO FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 238) | F-2 |
|---|---|
| Balance Sheets as of December 31, 2024 and 2023 | F-3 |
| Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023 | F-4 |
| Statements of Stockholders’ Equity for the years ended December 31, 2024 and 2023 | F-5 |
| Statements of Cash Flows for the years ended December 31, 2024 and 2023 | F-6 |
| Notes to the Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.